Published in J Dtsch Dermatol Ges on June 01, 2007
Mediterranean jellyfish venoms: a review on scyphomedusae. Mar Drugs (2010) 1.28
Immunological and toxinological responses to jellyfish stings. Inflamm Allergy Drug Targets (2011) 1.02
[Letter on Heidi Ulrich, Michael Landthaler, Thomas Vogt, "Granulomatosis Dermatitis from a Jellyfish"--JDDG 2007; 5: 493-495]. J Dtsch Dermatol Ges (2007) 0.75
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol (2003) 4.15
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell. J Invest Dermatol (2013) 2.31
Foreign body granulomas caused by polymethylmethacrylate microspheres: successful treatment with allopurinol. Arch Dermatol (2003) 2.23
Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem (2004) 2.17
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet (2012) 2.03
Cutaneous amyloidoses and systemic amyloidoses with cutaneous involvement. Eur J Dermatol (2010) 2.03
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A (2007) 1.97
Treatment of oral lichen planus with the 308-nm UVB excimer laser--early preliminary results in eight patients. Lasers Surg Med (2003) 1.79
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest (2006) 1.78
Tattoo pigments are cleaved by laser light-the chemical analysis in vitro provide evidence for hazardous compounds. Photochem Photobiol (2004) 1.66
Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. Eur Urol (2008) 1.65
KITLG mutations cause familial progressive hyper- and hypopigmentation. J Invest Dermatol (2011) 1.59
Tattooing of skin results in transportation and light-induced decomposition of tattoo pigments--a first quantification in vivo using a mouse model. Exp Dermatol (2009) 1.55
Whole-body UVB irradiation during allogeneic hematopoietic cell transplantation is safe and decreases acute graft-versus-host disease. J Invest Dermatol (2011) 1.51
Seborrheic keratosis. J Dtsch Dermatol Ges (2008) 1.49
Recent advances in betalain research. Phytochemistry (2003) 1.41
Dysplastic melanocytic nevi of the lower leg: sex- and site-specific histopathology. Am J Dermatopathol (2010) 1.40
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet (2012) 1.40
Intense pulsed light (IPL): a review. Lasers Surg Med (2010) 1.39
[Smoking -- effects on the skin]. J Dtsch Dermatol Ges (2003) 1.38
Gene expression profiling of melanocytes following Q-Switched Ruby laser irradiation. Dermatology (2008) 1.37
Dead Sea treatment - principle for outpatient use in atopic dermatitis: safety and efficacy of synchronous balneophototherapy using narrowband UVB and bathing in Dead Sea salt solution. Eur J Dermatol (2002) 1.37
High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol (2006) 1.37
Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol (2010) 1.31
Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control (2010) 1.28
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27
Occurence and clinical predictors of spasticity after ischemic stroke. Stroke (2010) 1.24
Singlet oxygen generation by UVA light exposure of endogenous photosensitizers. Biophys J (2006) 1.24
RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. Int J Cancer (2008) 1.22
Relationship between tobacco control policies and the delivery of smoking cessation services in nonprofit HMOs. J Natl Cancer Inst Monogr (2005) 1.22
Plasma medicine: possible applications in dermatology. J Dtsch Dermatol Ges (2010) 1.21
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer (2003) 1.20
Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol (2006) 1.20
The role of singlet oxygen and oxygen concentration in photodynamic inactivation of bacteria. Proc Natl Acad Sci U S A (2007) 1.20
Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol (2005) 1.16
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol (2010) 1.14
Incidence of health problems associated with tattooed skin: a nation-wide survey in German-speaking countries. Dermatology (2010) 1.14
Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses. J Invest Dermatol (2007) 1.13
Orofacial granulomatosis as the initial presentation of Crohn's disease in an adolescent. Dermatology (2003) 1.12
Selective photothermolysis of blood vessels following flashlamp-pumped pulsed dye laser irradiation: in vivo results and mathematical modelling are in agreement. J Invest Dermatol (2005) 1.12
Photodynamic therapy in dermatology. Eur J Dermatol (2006) 1.11
Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells. J Invest Dermatol (2006) 1.10
Photodynamic therapy in dermatology--an update. Photodermatol Photoimmunol Photomed (2005) 1.09
Wound healing in the 21st century. J Am Acad Dermatol (2010) 1.07
Simultaneous photographing of oxygen and pH in vivo using sensor films. Angew Chem Int Ed Engl (2011) 1.07
A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One (2012) 1.07
Loss of EphB6 expression in metastatic melanoma. Int J Oncol (2003) 1.06
Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Res (2009) 1.06
The spectrum of reticulate pigment disorders of the skin revisited. Eur J Dermatol (2012) 1.06
Adverse reactions after tattooing: review of the literature and comparison to results of a survey. Dermatology (2013) 1.06
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res (2007) 1.06
Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol (2008) 1.05
In vivo confocal scanning laser microscopy in dermatology. Lasers Med Sci (2006) 1.03
2D luminescence imaging of pH in vivo. Proc Natl Acad Sci U S A (2011) 1.03
Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One (2012) 1.02
Vitamin D receptor (VDR) polymorphisms and skin cancer: A systematic review. Dermatoendocrinol (2011) 1.02
A novel Mg(2+)-dependent O-methyltransferase in the phenylpropanoid metabolism of Mesembryanthemum crystallinum. J Biol Chem (2003) 1.02
Fibroadenoma of the axilla. Dermatol Surg (2005) 1.02
Heat shock protein 70 membrane expression and melanoma-associated marker phenotype in primary and metastatic melanoma. Melanoma Res (2003) 1.01
Pressure-induced volume expansion of zeolites in the natrolite family. J Am Chem Soc (2002) 1.01
FGFR3 mutations in benign skin tumors. Cell Cycle (2006) 1.00
Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci U S A (2010) 1.00
Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int J Oncol (2005) 0.99
Leg ulcers and abscesses caused by Serratia marcescens. Eur J Dermatol (2008) 0.99
IgE-mediated anaphylactic reaction induced by succinate ester of methylprednisolone. Ann Allergy Asthma Immunol (2002) 0.99
Biochemical and structural analysis of substrate promiscuity in plant Mg2+-dependent O-methyltransferases. J Mol Biol (2008) 0.99
Photodynamic therapy in dermatology: state-of-the-art. Photodermatol Photoimmunol Photomed (2010) 0.99
Structure of V(2)O(5)*nH(2)O xerogel solved by the atomic pair distribution function technique. J Am Chem Soc (2002) 0.98
Screening rarely screened women: time-to-service and 24-month outcomes of tailored interventions. Prev Med (2003) 0.98
The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol (2005) 0.98
Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer (2004) 0.97
Phenylpropanoid polyamine conjugate biosynthesis in Arabidopsis thaliana flower buds. Phytochemistry (2009) 0.97
Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron (2008) 0.97
Ephrin-B2 is differentially expressed in the intestinal epithelium in Crohn's disease and contributes to accelerated epithelial wound healing in vitro. World J Gastroenterol (2005) 0.96
FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from urothelium and skin. J Invest Dermatol (2007) 0.95
Influence of 5-aminolevulinic acid and red light on collagen metabolism of human dermal fibroblasts. J Invest Dermatol (2003) 0.95
Screening for iron overload: lessons from the hemochromatosis and iron overload screening (HEIRS) study. Can J Gastroenterol (2009) 0.95